Houda Hachad, VP of Clinical Operations at Aranscia, AccessDx Laboratory’s parent company, is a co-author of the recent paper focusing on CYP3A4 and CYP3A5 genotyping recommendations in collaboration with the Association for Molecular Pathology Clinical Practice Committee’s Pharmacogenomics (PGx) Working Group.
Per the paper, “The goals of the Association for Molecular Pathology Clinical Practice Committee’s Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays.”
To read the full paper in PubMed, click here: https://pubmed.ncbi.nlm.nih.gov/37419245/
